Chinese GPs are running low on exit options, but the barriers to unconventional routes â€“ like secondary sales to other GPs â€“ remain high.
By Michelle Phillips
Chinaâ€™s exit woes are no secret. With accounting scandals freezing the IPO route both abroad and domestically, the waiting list for IPO approval on Chinaâ€™s stock exchanges has come close to 900 companies.Â Fund managers have at least 7,550 unexited investments worth a combined $100 billion, according to a recent study by China First Capital. However, including undisclosed deals, the number of companies could be as high as 10,000, says CFCâ€™s founder and chairman Peter Fuhrman.
CITIC Capital chief executive Yichen Zhang told the Hong Kong Venture Capital Association Asia Private Equity Forum in January that because many GPs promised high returns in an unrealistic timeframe (usually three to five years), LPs were already starting to get impatient. He also predicted that around 80 percent of Chinaâ€™s smaller GPs would collapse in the coming years. â€œThe worst is yet to come,â€ he said.
What ought to become an attractive option for these funds, according to the CFC study, are secondary buyouts. Even if it lowers the exit multiple, secondaries would provide liquidity for LPs, as well as potentially giving the companies an influx of cash, Fuhrman says.